21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
22:43 , Apr 23, 2018 |  BC Extra  |  Clinical News

FDA places hold on Epizyme's tazemetostat

Epizyme Inc. (NASDAQ:EPZM) fell $2.90 (19%) to $12.40 in after-hours trading Monday after FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438) following a report of a patient who developed secondary T cell lymphoma...
20:27 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

Daiichi reports Phase I data for DS-3201 in NHL

Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported preliminary data from 17 evaluable patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) in an open-label, dose-escalation, Japanese Phase I trial showing that DS-3201 led to overall response rate...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
18:57 , Oct 27, 2017 |  BC Week In Review  |  Company News

Daiichi and MD Anderson partner to develop AML candidates

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and the University of Texas MD Anderson Cancer Center (Houston, Texas) partnered to develop multiple therapies for acute myelogenous leukemia (AML). During the multiyear collaboration, MD Anderson is to conduct...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
01:12 , Jul 15, 2017 |  BC Extra  |  Preclinical News

Paper ties EZH1, vHL to synthetic lethality in RCC

In a paper published in Science Translational Medicine , scientists showed that inhibition of enhancer of zeste homolog 1 (EZH1) prevented proliferation in von Hippel-Lindau tumor suppressor (vHL)-mutant clear cell renal cell carcinoma, suggesting that...
08:00 , Jan 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Diffuse large B cell lymphoma (DLBCL) Enhancer of zeste homolog 2 (EZH2) In vitro studies identified an EZH2 inhibitor that could...